<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555422</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-024</org_study_id>
    <secondary_id>ENGOT-EN5</secondary_id>
    <secondary_id>BGOG-EN5</secondary_id>
    <secondary_id>2017-000607-25</secondary_id>
    <nct_id>NCT03555422</nct_id>
  </id_info>
  <brief_title>Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]</brief_title>
  <acronym>ENGOT-EN5</acronym>
  <official_title>A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belgium and Luxembourg Gynaecological Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North-Eastern German Society of Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Research Group in Ovarian Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Central and Eastern European Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Israel Society of Gynecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The GOG Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3&#xD;
      study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor&#xD;
      in participants with advanced or recurrent endometrial cancer. Participants with primary&#xD;
      stage IV or recurrent disease who are in partial or complete response after having completed&#xD;
      a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized in a&#xD;
      2:1 manner to maintenance therapy with 80 milligram (mg) with selinexor once weekly (QW) or&#xD;
      placebo until progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind placebo controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Compare progression free survival of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival: Assessed by Blinded Independent Central Review (BICR), per RECIST v1.1</measure>
    <time_frame>Time from randomization until PD or death, whichever occurs first (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until documented PD or death due to any cause, whichever occurs first. Documented PD will be based on BICR assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Survival (DSS)</measure>
    <time_frame>Time from randomization until death from endometrial cancer (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until date of death from endometrial cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time from randomization until death (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Subsequent Treatment (TFST)</measure>
    <time_frame>Time from randomization until first therapy initiation after discontinuation of study drug or death, whichever occurs first (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival After Subsequent Treatment (PFS2)</measure>
    <time_frame>Time from randomization until second documented PD or death (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until the second documented disease progression or death due to any cause by any cause on any subsequent line of anticancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Second Subsequent Treatment (TSST)</measure>
    <time_frame>Time from randomization until second therapy initiation after discontinuation of study drug or death, whichever occurs first (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Time from randomization up to approximately 16 weeks</time_frame>
    <description>Best response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) among patients with PR as best response to prior chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HR-QoL): Measured by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30</measure>
    <time_frame>Every 12 weeks during study period, at PD and post PD at 3 and 6 months (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Patient-reported outcomes will be measured by the EORTC QLQ C30 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life: Measured by EORTC QLQ-EN24</measure>
    <time_frame>Every 12 weeks during study period, at PD and post PD at 3 and 6 months (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Patient-reported outcomes will be measured by the EORTC QLQ-EN24 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life: Measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)</measure>
    <time_frame>Every 12 weeks during study period, at PD and post PD at 3 and 6 months (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Patient-reported outcomes will be measured by the EORTC EQ-5D-5L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events (TEAEs), Occurrence, Nature, and Severity of AEs</measure>
    <time_frame>From first drug administration up to 30 days after last dose (approximately 12 months after the last patient enrolled)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Significant Physical Examination, Clinical Laboratory, and Vital Signs Results</measure>
    <time_frame>From first drug administration up to 30 days after last dose (approximately 12 months after the last patient enrolled)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Selinexor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive fixed dose of selinexor 80 mg (or 60 mg for participants with a body mass index [BMI] less than [&lt;] 20 kilogram per meter square [kg/m^2]) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo for selinexor</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral</description>
    <arm_group_label>Selinexor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo for selinexor</intervention_name>
    <description>Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral</description>
    <arm_group_label>Matching placebo for selinexor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, at least 18 years of age at the time of informed consent.&#xD;
&#xD;
          -  Histological confirmed endometrial cancer of the endometrioid, serous, or&#xD;
             undifferentiated type. Carcinosarcoma of the uterus is also allowed.&#xD;
&#xD;
          -  Completed a single line of at least 12 weeks of taxane-platinum combination therapy&#xD;
             (not including adjuvant or neoadjuvant therapy), and achieved partial remission (PR)&#xD;
             or complete remission (CR) according to RECIST version 1.1 for:&#xD;
&#xD;
          -  Primary Stage IV disease, defined as:&#xD;
&#xD;
          -  had a primary or later debulking surgery during first-line taxane-platinum therapy&#xD;
             with R0 resection (R0 resection indicates a macroscopic complete resection of all&#xD;
             visible tumor) and achieved CR after at least 12 weeks taxane-platinum chemotherapy,&#xD;
             OR&#xD;
&#xD;
          -  had a primary or later debulking surgery during first-line taxane-platinum therapy&#xD;
             with R1 resection (R1 resection indicates incomplete removal of all macroscopic&#xD;
             disease,) and achieved PR or CR after at least 12 weeks taxane-platinum chemotherapy,&#xD;
             OR&#xD;
&#xD;
          -  had no surgery and achieved PR or CR after at least 12 weeks taxane-platinum&#xD;
             chemotherapy.&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  At first relapse (i.e., relapse after primary therapy including surgery and/or&#xD;
             chemotherapy therapy for Stage I-IV disease), defined as:&#xD;
&#xD;
          -  had Stage I-III disease at diagnosis and received at initial diagnosis adjuvant&#xD;
             chemotherapy and relapsed later. Participants should have PR or CR after at least 12&#xD;
             weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy at&#xD;
             the time of relapse, OR&#xD;
&#xD;
          -  had Stage I-III disease at diagnosis and did not receive adjuvant chemotherapy at&#xD;
             initial diagnosis and relapsed later. Participants should have PR or CR after at least&#xD;
             12 weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy&#xD;
             at the time of relapse, OR&#xD;
&#xD;
          -  had Stage IV disease at diagnosis and received initially chemotherapy with or without&#xD;
             surgery and relapsed later. At the time of relapse, participants should have PR or CR&#xD;
             after at least 12 weeks of taxane-platinum chemotherapy compared with the start of&#xD;
             this chemotherapy at the time of relapse.&#xD;
&#xD;
        Participants that required their chemotherapy dose held during the 12-week therapy may be&#xD;
        considered if they meet the other criteria above and achieve PR or CR per RECIST V1.1.&#xD;
&#xD;
          -  Must be able to initiate study drug 5 to 8 weeks after completion of their final dose&#xD;
             of chemotherapy.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          -  Participants must have adequate bone marrow function and organ function within 2 weeks&#xD;
             before starting study drug as defined by the following laboratory criteria:&#xD;
&#xD;
          -  Hepatic function: total bilirubin up to 1.5*upper limit of normal (ULN); alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to (≤)&#xD;
             2.5*ULN in participants without liver metastasis. For participants with known liver&#xD;
             involvement of their tumor: AST and ALT ≤5*ULN.&#xD;
&#xD;
          -  Hematopoetic function: Absolute neutrophil count (ANC) greater than or equal to (≥)&#xD;
             1.5*10^9/L; platelet count ≥100*10^9 per liter (/L); hemoglobin ≥9.0 gram per&#xD;
             deciliter (g/dL).&#xD;
&#xD;
          -  Renal function: estimated creatinine clearance (CrCl) of ≥20 milliliter per minute&#xD;
             (mL/min), calculated using the Cockroft Gault formula.&#xD;
&#xD;
          -  In the opinion of the Investigator, the participant must:&#xD;
&#xD;
          -  Have a life expectancy of at least 12 weeks, and&#xD;
&#xD;
          -  Be fit to receive experimental therapy.&#xD;
&#xD;
          -  Premenopausal females of childbearing potential must have a negative pregnancy test&#xD;
             (serum β-human chorionic gonadotropin test) prior to the first dose of study drug.&#xD;
             Female participants of childbearing potential must agree to use highly effective&#xD;
             methods of contraception throughout the study and for 1 week following the last dose&#xD;
             of study drug.&#xD;
&#xD;
          -  Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines. The participant must provide informed consent prior to the first Screening&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has any sarcomas, small cell carcinoma with neuroendocrine differentiation, or clear&#xD;
             cell carcinomas.&#xD;
&#xD;
          -  Received a blood or platelet transfusion during 4 weeks prior to randomization.&#xD;
&#xD;
          -  Being treated with a concurrent cancer therapy.&#xD;
&#xD;
          -  Previous treatment with an exportin 1 (XPO1) inhibitor.&#xD;
&#xD;
          -  Previous treatment with anti- programmed cell death protein 1 (PD-1) or&#xD;
             anti-programmed cell death ligand-1 (PD-L1) immunotherapy (e.g., pembrolizumab).&#xD;
&#xD;
          -  Concurrent treatment with an investigational agent or participation in another&#xD;
             clinical trial.&#xD;
&#xD;
          -  Participants who received any systemic anticancer therapy including investigational&#xD;
             agents or radiation ≤3 weeks (or ≤5 half-lives of the drug [whichever is shorter])&#xD;
             prior to cycle 1 day 1 (C1D1). Palliative radiotherapy may be permitted for&#xD;
             symptomatic control of pain from bone metastases in extremities, provided that the&#xD;
             radiotherapy does not involve target lesions, and the reason for the radiotherapy does&#xD;
             not reflect progressive disease (PD).&#xD;
&#xD;
          -  Major injuries or surgery within 14 days prior to C1D1 and/or planned surgery during&#xD;
             the on-treatment study period.&#xD;
&#xD;
          -  Previous malignant disease, except participants with other malignant disease, for&#xD;
             which the participant has been disease-free for at least 3 years. Concurrent other&#xD;
             malignant disease except for curatively treated carcinoma in situ of the cervix or&#xD;
             basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Any life-threatening illness, medical condition or organ system dysfunction, which, in&#xD;
             the investigator's opinion, could compromise the participant's safety or compliance&#xD;
             with the protocol.&#xD;
&#xD;
          -  Known contraindications to selinexor.&#xD;
&#xD;
          -  Known uncontrolled hypersensitivity to the investigational drug, or to its excipients.&#xD;
&#xD;
          -  Radiotherapy to the target lesion within the past 3 months prior to baseline imaging.&#xD;
&#xD;
          -  Persistent Grade 3 or 4 toxicity from previous chemotherapy and/or radiotherapy, with&#xD;
             the exception of alopecia.&#xD;
&#xD;
          -  Active brain metastases (e.g., stable for &lt;8 weeks, no adequate previous treatment&#xD;
             with radiotherapy and/or surgery, symptomatic, requiring treatment with&#xD;
             anti-convulsants. Corticoid therapy is allowed if administered as stable dose for at&#xD;
             least 1 month before randomization).&#xD;
&#xD;
          -  Known unstable cardiovascular function:&#xD;
&#xD;
          -  Symptomatic ischemia, or&#xD;
&#xD;
          -  Uncontrolled clinically significant conduction abnormalities (i.e., ventricular&#xD;
             tachycardia on anti-arrhythmia are excluded; 1st degree atrioventricular block or&#xD;
             asymptomatic left anterior fascicular block /right bundle branch block will not be&#xD;
             excluded), or&#xD;
&#xD;
          -  Congestive heart failure of New York Heart Association Class ≥3, or&#xD;
&#xD;
          -  Myocardial infarction within 3 months&#xD;
&#xD;
          -  Females who are pregnant or actively breastfeeding.&#xD;
&#xD;
          -  Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics,&#xD;
             antivirals, or antifungals within 1 week prior to first dose; however, prophylactic&#xD;
             use of these agents is acceptable even if parenteral.&#xD;
&#xD;
          -  Active hepatitis C and/or B infection.&#xD;
&#xD;
          -  Participants unable to swallow tablets, participants with malabsorption syndrome, or&#xD;
             any other gastrointestinal (GI) disease or GI dysfunction that could interfere with&#xD;
             absorption of study drug. A history of bowel obstruction requiring a nasogastric tube&#xD;
             or intravenous infusion during the past 2 months is not allowed (except when this&#xD;
             obstruction is caused by surgery or other non-malignant causes).&#xD;
&#xD;
          -  Psychiatric illness or substance use that would prevent the participant from giving&#xD;
             informed consent or being compliant with the study procedures.&#xD;
&#xD;
          -  Participants unwilling or unable to comply with the protocol.&#xD;
&#xD;
          -  Persons who have been committed to an institution by official or judicial order.&#xD;
&#xD;
          -  Participants with dependency on the Sponsor, Investigator or study site.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jatin Shah, Executive Vice President and Chief Medical Officer, MD</last_name>
    <phone>(617) 658-0600</phone>
    <email>jshah@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, Chief Scientific Officer, PhD</last_name>
    <phone>(617) 658-0600</phone>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HAL</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Fellers</last_name>
      <phone>602-277-4868</phone>
      <email>Leslie.Fellers@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Monk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Klinker</last_name>
      <phone>520-269-3821</phone>
      <email>julie.klinker@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Buscema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92882</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Tieng</last_name>
      <phone>562-693-4477</phone>
      <email>stieng@icrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Gilmore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Aidasani</last_name>
      <phone>650-723-0594</phone>
      <email>aidasani@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Berek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope &amp; Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Tieng</last_name>
      <phone>562-693-4477</phone>
      <email>stieng@icrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Merrill Shum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center Inc</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Reyes</last_name>
      <phone>561-447-0614</phone>
      <email>vreyes@brcrglobal.com</email>
    </contact>
    <investigator>
      <last_name>Harshad Amin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazmin Rodriguez</last_name>
      <phone>813-745-4673</phone>
      <email>Yazmin.Rodriguez@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hye Sook Chon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists (Sarah Cannon Research Institute)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Shaw</last_name>
      <phone>615-524-4016</phone>
      <email>colleen.shaw@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Spitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Cuvo</last_name>
      <phone>404-236-8304</phone>
      <email>jennifer.cuvo@northside.com</email>
    </contact>
    <investigator>
      <last_name>Meaghan Tenney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Wheatley</last_name>
      <email>dwheatley@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Sharad Ghamande</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sudarshan K. Sharma, Ltd</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peg Gregus</last_name>
      <email>peggregus@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sudarshan Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynecological Cancer Institute of Chicago</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Schupp</last_name>
      <email>mschupp@gcichicago.com</email>
    </contact>
    <investigator>
      <last_name>Alfred Guirguis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Sanders</last_name>
      <phone>317-278-2351</phone>
      <email>kmb9@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Landrum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Wolgasta</last_name>
      <email>wolgasta@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Radhika Gogoi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covenant HealthCare</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wasmiller</last_name>
      <phone>989-583-6494</phone>
      <email>swasmiller@chs-mi.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Sutton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health - Kansas City (Sarah Cannon Research Institute)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Huntley</last_name>
      <phone>702-822-2237</phone>
      <email>Carol.Huntley@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Restituto Tibayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Care Associates, LLC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolina Suriano</last_name>
      <email>nsuriano@womenscancercareassociates.com</email>
    </contact>
    <investigator>
      <last_name>Joyce Barlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyanka Patel</last_name>
      <phone>212-731-6155</phone>
      <email>priyanka.patel@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Bhavana Pothuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Li</last_name>
      <phone>646-735-8278</phone>
      <email>Lik2@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Vicky Makker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bundus</last_name>
      <phone>513-584-7847</phone>
      <email>bundusla@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Jackson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Hays</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>48963</phone_ext>
      <email>Morgan-Hays@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Debra Richardson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Associates of Oregon</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roosevelt Anderson</last_name>
      <phone>541-683-5001</phone>
      <email>Roosevelt.Anderson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Charles Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siobhan Guyach</last_name>
      <email>siobhan.guyach@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Eirwen Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Beltran</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>48181</phone_ext>
      <email>abeltran@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Katina Robison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Byers</last_name>
      <email>ebyers@utmck.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Boone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Nashville (Sarah Cannon Research Institute)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Shaw</last_name>
      <phone>615-524-4016</phone>
      <email>colleen.shaw@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisca Fernandez</last_name>
      <phone>512-427-9400</phone>
      <email>Francisca.Fernandez@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Teneriello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Wright</last_name>
      <phone>214-370-1000</phone>
      <email>jennifer.wright2@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Mathews</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Kyle</last_name>
      <phone>214-648-7094</phone>
      <email>Kelly.Kyle@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Forth Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nori Sullivan</last_name>
      <phone>817-413-1500</phone>
      <email>nori.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Noelle Cloven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Bock</last_name>
      <phone>210-595-5300</phone>
      <email>alice.bock@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph de la Garza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lopez</last_name>
      <phone>281-296-0365</phone>
      <email>ruth.lopez1@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christine Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Maxfield</last_name>
      <phone>903-579-9800</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anna Priebe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mastro</last_name>
      <email>masseyactpm@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Randall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny Bustin</last_name>
      <phone>32 (0)2 541 31 42</phone>
      <email>fanny.bustin@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Joseph Kerger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita De Letter</last_name>
      <phone>003293328951</phone>
      <email>rita.deletter@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Hannerlore Denys</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jan Yperman Ziekenhuis</name>
      <address>
        <city>Ieper</city>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marijke Ghekiere</last_name>
      <phone>003257357300</phone>
      <email>marijke.ghekiere@yperman.net</email>
    </contact>
    <investigator>
      <last_name>Debbie Debaere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen K.U. Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Lefever</last_name>
      <phone>3216347680</phone>
      <email>inge.lefever@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Toon Van Gorp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Blockmans</last_name>
      <phone>003265417510</phone>
      <email>marianne.blockmans@hap.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Cornez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur, Site Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedicte Hyernaux</last_name>
      <phone>32 (0)81 70 28 24</phone>
      <email>benedicte.hyernaux@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Stephanie Henry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Geentjens</last_name>
      <phone>003214406912</phone>
      <email>sarah.geentjens@azturnhout.be</email>
    </contact>
    <investigator>
      <last_name>Isabelle Cadron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Verviers</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Rouchet</last_name>
      <phone>003287212768</phone>
      <email>nathalie.rouchet@chrverviers.be</email>
    </contact>
    <investigator>
      <last_name>Annelore Barbeaux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta; Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Silvius</last_name>
      <phone>780-432-8349</phone>
      <email>ashley.silvius@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Kolinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre (London Regional Cancer Centre)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Ogorman</last_name>
      <phone>519-685-8618</phone>
      <email>jennifer.ogorman@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Welch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network (PMCC)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hashaam Hasan</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>3910</phone_ext>
      <email>hashaam.hasan@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Amit Oza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor Grant</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>31975</phone_ext>
      <email>taylor.grant@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Lucy Gilbert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Maternal and Child Health Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaijia Tu</last_name>
      <phone>13576262749</phone>
      <email>tukaijia@sina.com</email>
    </contact>
    <investigator>
      <last_name>Kaijia Tu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danbo Wang</last_name>
      <phone>18940251157</phone>
      <email>danbo_wang@126.com</email>
    </contact>
    <investigator>
      <last_name>Danbo Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Shapingba District</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhou</last_name>
      <phone>189 0838 4529</phone>
      <email>qizhou9128@163.com</email>
    </contact>
    <investigator>
      <last_name>Qi Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Tomkova</last_name>
      <phone>+420 532238386</phone>
      <email>tomkova.martina@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Vit Weinberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palacky University Hospital</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Jaskova</last_name>
      <phone>+420 588 443 895</phone>
      <email>petra.jaskova@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Bohuslav Melichar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aneta Nenickova</last_name>
      <phone>+420597375852</phone>
      <email>aneta.nenickova@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Jaroslav Klat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Královské Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaudie Reginacova</last_name>
      <phone>420 604 655 677</phone>
      <email>klaudia.reginacova@fnkv.cz</email>
    </contact>
    <investigator>
      <last_name>Klaudie Reginacova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <zip>12851</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Stribrna</last_name>
      <phone>+420 224 969 298</phone>
      <email>jana.stribrna@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>David Cibula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Na Bulovce</name>
      <address>
        <city>Prague</city>
        <zip>18081</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hana Urbankova</last_name>
      <phone>+420 608 552 828</phone>
      <email>hana.urbankova@bulovka.cz</email>
    </contact>
    <investigator>
      <last_name>Michal Zikan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Berlin Universitatsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maria</last_name>
      <phone>493 086800 1402</phone>
      <email>anna-maria.mira-conti@charite.de</email>
    </contact>
    <investigator>
      <last_name>Jalid Sehouli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Schubert</last_name>
      <phone>49 351 4584202</phone>
      <email>olga.schubert@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Pauline Wimberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DIAKOVERE KH gGmbH, Henriettenstift Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willi Pollack</last_name>
      <phone>+49 511 289 3455</phone>
      <email>willi.pollack@diakovere.de</email>
    </contact>
    <investigator>
      <last_name>Kristina Luebbe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ViDia Christliche Kliniken Karlsruhe Vincentius-Diakonissen-Kliniken g AG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilli Funk</last_name>
      <phone>+49 721 8108 8760</phone>
      <email>lilli.funk@vincentius-ka.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Tome</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Schmidt</last_name>
      <phone>49 431 50021683</phone>
      <email>tobias.schmidt@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Dirk Bauerschlag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Eberhardt</last_name>
      <phone>+49 341 9723937</phone>
      <email>Iris.Eberhardt@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Bahriye Aktas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Mros</last_name>
      <phone>+49 6131 175581</phone>
      <email>bettina.mros@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Marco Battista</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Munchen</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Gansneder</last_name>
      <phone>+49 89 4400 76725</phone>
      <email>bettina.gansneder@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Fabian Trillsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cartitas Klinikum Saarbrücken</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Schilling</last_name>
      <phone>+49 681 406 1345</phone>
      <email>u.schilling@caritasklinikum.de</email>
    </contact>
    <investigator>
      <last_name>Mustafa Deryal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica D'Andrea</last_name>
      <phone>+49 731 500 58521</phone>
      <email>jessica.dandrea@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Nikolaus de Gregorio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iaso Hospital</name>
      <address>
        <city>Maroussi</city>
        <state>Athens</state>
        <zip>151 23</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angeliki Konte</last_name>
      <phone>6977679673</phone>
      <email>aggelikikonte@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Christos Papadimitriou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Euromedica General Clinic</name>
      <address>
        <city>Thessaloniki</city>
        <state>Macedonia</state>
        <zip>54645</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastasia Kitka</last_name>
      <phone>302310850906</phone>
      <email>nkitka@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>George Fountzilas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ALEXANDRA Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Styliani Verarou</last_name>
      <phone>+30 6942463446</phone>
      <email>verarou@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Flora Zagouri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Patras Agios Andreas</name>
      <address>
        <city>Patra</city>
        <zip>26335</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elefleria Tsati</last_name>
    </contact>
    <contact_backup>
      <phone>6981367665</phone>
      <email>tsatieleftheria@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Athena Christopoulou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagit Stolz</last_name>
      <phone>972-52-6377061</phone>
      <email>hagitst@hy.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ilan Bruchim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Sachakov</last_name>
      <phone>972-3-5028408</phone>
      <email>mariasa@wmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tally Levy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yair Plesser</last_name>
      <phone>972-2-6555727</phone>
      <email>yairp@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Ora Rosengarten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat -Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hila Sabag</last_name>
      <phone>972-50-7649502</phone>
      <email>vera.leibo@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Limor Helpman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagit Damchiner</last_name>
      <phone>972-3-697615</phone>
      <email>hagitdp@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tamar Safra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo, FPO, IRCCS</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cosimo Martino</last_name>
      <phone>0039 0119933842</phone>
      <email>cosimo.martino@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Giorgio Valabrega</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Romagnolo Scientific Institute for the Study and Treatment of Tumors</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgia Ravaglia</last_name>
      <phone>0039 0543731075</phone>
      <email>giorgia.ravaglia@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Ugo de Giorgi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgia Lupi</last_name>
      <phone>00393381027156</phone>
      <email>lupi.giorgia@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Giorgia Mangili</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori IRCCS - MILANO S.C. Ginecologia Oncologica</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Ronzulli</last_name>
      <phone>+39 0223903825</phone>
      <email>Dominique.Ronzulli@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Raspagliesi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS 3 SERENISSIMA UOC Oncologia Ed Ematologia Oncologica</name>
      <address>
        <city>Mirano</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Coccato</last_name>
      <phone>0039 041 5794433</phone>
      <email>silvia.coccato@aulss3.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Lucia Borgato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS &quot;Fondazione G. Pascale&quot; - NAPOLI Struttura Complessa Oncologia Medica Uro-Ginecologica</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margherita Tambaro</last_name>
      <phone>0039 0815903637</phone>
      <email>m.tambaro@istitutotumori.na.it</email>
    </contact>
    <investigator>
      <last_name>Carmela Pisano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Agostino Gemelli University Polyclinic Foundation</name>
      <address>
        <city>Rome</city>
        <zip>30161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Garibaldi</last_name>
      <phone>0039 063015 8545</phone>
      <email>francesca.garibaldi@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Scambia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Díez</last_name>
      <phone>34 943 00 60 32</phone>
      <email>maria.diez@biodonostia.org</email>
    </contact>
    <investigator>
      <last_name>Nera Ancizar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thais Miquel</last_name>
      <phone>34 93 274 6000</phone>
      <phone_ext>4691</phone_ext>
      <email>tmiquel@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Ana Oaknin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Berengue</last_name>
      <phone>+34 93.227.54.00</phone>
      <phone_ext>2811</phone_ext>
      <email>BERENGUE@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Lydia Gaba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Barcelona</city>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carme Aracil</last_name>
      <phone>34 93-700-36-12</phone>
      <email>caracil@cst.cat</email>
    </contact>
    <investigator>
      <last_name>Emma Dotor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Navarro</last_name>
      <phone>+34 91 336 82 63</phone>
      <email>mncarmena@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Eva Guerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berenice Brihuega Arribas</last_name>
      <phone>0034 911917418</phone>
      <email>bbrihuega@idiphim.org</email>
    </contact>
    <investigator>
      <last_name>Constanza Maximiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>Madrid</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Perez</last_name>
      <phone>0034 911914243</phone>
      <email>lperez_ec@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Cesar Gomez-Raposo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virgen de la Arrixaca University Clinical Hospital</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Ruiz Carreño</last_name>
      <phone>+34 968 36 93 87</phone>
      <email>dm.oncoarrixaca@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeronimo Martinez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma</city>
        <zip>071998</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Ayuga</last_name>
      <phone>34 871202000</phone>
      <phone_ext>1629</phone_ext>
      <email>sayuga@hsll.es</email>
    </contact>
    <investigator>
      <last_name>Maria Iglesias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Rodríguez</last_name>
      <phone>34 955013068</phone>
      <email>econcologia.huvr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Purificacion Estevez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Mallol</last_name>
      <phone>34 961104606</phone>
      <email>coordinacion@fincivo.org</email>
    </contact>
    <investigator>
      <last_name>Ignacio Romero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celia Martinez</last_name>
      <phone>0034 961973527</phone>
      <email>cmartinez@incliva.es</email>
    </contact>
    <investigator>
      <last_name>Jose Alejandro Perez-Fidalgo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico de La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Lavin</last_name>
      <phone>34 961244188</phone>
      <email>ckm.nival@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Santaballa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Huércanos</last_name>
      <phone>+34 976 76 57 69</phone>
      <email>ihuercanos@iisaragon.es</email>
    </contact>
    <investigator>
      <last_name>Alfonso Yubero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial Neoplasms</keyword>
  <keyword>Uterine Neoplasms</keyword>
  <keyword>Genital Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Uterine Diseases</keyword>
  <keyword>Genital Diseases</keyword>
  <keyword>Female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

